Yonis Bliss

The dosage of Matricaria Recutita varies significantly based on the intended clinical use and the specific formulation prescribed by a healthcare provider.

• For Allergy Testing (Diagnostic): The standard concentration for skin prick testing is typically 1:10 or 1:20 w/v (weight/volume). For intradermal testing, the concentration is much lower, often ranging from 0.01 mL to 0.05 mL of a highly diluted extract (e.g., 100 to 1000 PNU/mL).
• For Systemic Use (Oral): When used for its estrogenic or nitrogen-binding properties, typical adult doses range from 220 mg to 1600 mg daily, often divided into two or three doses. Standardized extracts should contain a specific percentage of apigenin (usually 1.2%).
• For Immunotherapy: Dosing follows a "build-up" phase where the dose is gradually increased over several weeks, followed by a maintenance phase. Maintenance doses are highly individualized based on patient tolerance.

Matricaria Recutita should be used with extreme caution in pediatric populations.

• Allergy Testing: Pediatric dosing for skin testing is generally similar to adult dosing in terms of concentration, but the number of tests performed at one time may be limited to reduce the risk of systemic reactions.
• Systemic Use: There is limited clinical data regarding the safety of systemic Matricaria Recutita in children under the age of 12. Healthcare providers typically avoid its use in this population unless the benefit clearly outweighs the risk.

Renal Impairment

Since approximately 70% of Matricaria Recutita metabolites are excreted via the kidneys, patients with impaired renal function (CrCl < 30 mL/min) may require a dose reduction of 25-50% to prevent accumulation and potential toxicity. Monitoring of renal function markers is recommended during long-term therapy.

Hepatic Impairment

Because the drug is metabolized by CYP450 enzymes, patients with moderate to severe hepatic impairment (Child-Pugh Class B or C) should be closely monitored. Dose adjustments may be necessary, and clinicians may prefer lower starting doses to assess tolerance.

Elderly Patients

Geriatric patients often have reduced physiological reserves and may be more sensitive to the estrogenic effects of Matricaria Recutita. Dosing should start at the lower end of the spectrum, with careful monitoring for cardiovascular and bone density changes.

• Injectable/Diagnostic: These must only be administered by a trained healthcare professional in a clinical setting equipped to handle anaphylaxis.
• Oral Forms: Should be taken with a full glass of water. While it can be taken with or without food, taking it with a light meal may reduce potential gastrointestinal upset. Do not crush or chew standardized tablets unless specifically instructed.
• Storage: Store at room temperature (20°C to 25°C / 68°F to 77°F) away from direct sunlight and moisture. Injectable forms may require refrigeration (2°C to 8°C) as per the manufacturer's instructions.

If you miss a dose of an oral formulation, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up. For missed immunotherapy injections, contact your allergist immediately to determine if the dose needs to be adjusted downward for safety.

Signs of an overdose of Matricaria Recutita may include severe nausea, vomiting, dizziness, and in extreme cases, signs of estrogenic excess such as breast tenderness or abnormal uterine bleeding. In the context of an allergenic extract injection, an overdose may manifest as systemic anaphylaxis (difficulty breathing, swelling of the throat, rapid drop in blood pressure). In the event of a suspected overdose, seek emergency medical attention or contact a poison control center immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as this could interfere with diagnostic results or therapeutic efficacy.

Patients taking Matricaria Recutita, particularly in oral or topical forms, may experience several common side effects. These are generally mild and self-limiting:

• Gastrointestinal Upset: Nausea, mild abdominal cramping, or bloating. This typically occurs shortly after oral ingestion and subsides as the body adjusts to the medication.
• Local Irritation: When used topically or via skin testing, redness (erythema), itching (pruritus), and minor swelling at the application site are expected. This is often the desired diagnostic response in allergy testing.
• Drowsiness: Due to its mild sedative properties, some patients may feel slightly tired or relaxed. This effect is usually more pronounced in the first few days of treatment.

• Dermatological Reactions: Generalized skin rash or hives (urticaria) that are not limited to the site of administration.
• Hormonal Fluctuations: Some patients may experience mild breast tenderness or changes in menstrual cycle timing due to the Estrogen [EPC] activity.
• Headache: A dull, aching sensation that may persist for several hours after dosing.

• Severe Hypotension: A significant drop in blood pressure, usually associated with an allergic reaction to the extract itself.
• Paradoxical Excitation: In rare cases, especially in pediatric or geriatric patients, the drug may cause restlessness or insomnia instead of sedation.
• Hepatotoxicity: Rare elevations in liver enzymes have been reported with extremely high-dose, long-term systemic use.

> Warning: Stop taking Matricaria Recutita and call your doctor immediately if you experience any of these serious symptoms.

• Anaphylaxis: This is the most critical risk associated with Matricaria Recutita, especially when used as an allergenic extract. Symptoms include swelling of the face, lips, or tongue; difficulty breathing or swallowing; wheezing; and a rapid, weak pulse.
• Severe Uterine Bleeding: Due to its Estrogen [EPC] and Progesterone [EPC] activity, any unusual or heavy vaginal bleeding should be evaluated immediately to rule out endometrial hyperplasia.
• Thromboembolism: Signs of a blood clot, such as sudden pain and swelling in one leg, chest pain, or sudden shortness of breath. Estrogen-containing compounds can increase the risk of clotting in susceptible individuals.
• Severe Dizziness or Fainting: May indicate a systemic cardiovascular response or a severe allergic reaction.

Prolonged use of Matricaria Recutita may lead to certain chronic conditions. Because of its estrogenic profile, there is a theoretical risk of influencing hormone-sensitive tissues over many years. Regular monitoring of bone density and cardiovascular markers is recommended for those on long-term systemic therapy. Additionally, chronic use of allergenic extracts can occasionally lead to "delayed-type" hypersensitivity reactions, where the body becomes more sensitized to the allergen over time rather than desensitized.

While Matricaria Recutita itself may not always carry a specific black box warning in its botanical form, when processed as a Standardized Allergenic Extract, it falls under the general FDA class warning for allergenic extracts:

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

Matricaria Recutita allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients should be observed for at least 30 minutes following administration. This product should only be administered by healthcare professionals prepared to manage life-threatening systemic reactions. Patients with unstable or severe asthma may be at increased risk for severe reactions.

Report any unusual symptoms or persistent side effects to your healthcare provider to ensure your treatment plan remains safe and effective.

Matricaria Recutita is a potent pharmacological agent that requires careful clinical oversight. Patients must be aware that its classification as both an allergen and a hormone modulator means it can affect multiple organ systems simultaneously. It is vital to disclose your full medical history, including any history of asthma, cardiovascular disease, or hormone-sensitive cancers, to your healthcare provider before beginning treatment.

As noted, Matricaria Recutita in its capacity as a Standardized Allergenic Extract carries a significant risk of anaphylaxis. The FDA requires that these extracts be administered only in settings where emergency resuscitative equipment and trained personnel are immediately available. Patients must remain under medical supervision for a minimum of 30 minutes post-injection, as most life-threatening reactions occur within this window.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known allergy to members of the Asteraceae/Compositae family (e.g., ragweed, daisies, marigolds) are at a significantly higher risk of cross-reactivity and severe allergic reactions when using Matricaria Recutita.
• Asthma Status: Patients with uncontrolled or severe asthma are at a heightened risk for a fatal systemic reaction following the administration of allergenic extracts. Asthma must be stabilized before diagnostic testing or immunotherapy begins.
• Hormone-Sensitive Conditions: Due to its Estrogen [EPC] and Progesterone [EPC] properties, Matricaria Recutita should be used with caution in patients with a history of breast cancer, uterine cancer, or endometriosis. The estrogenic activity may stimulate the growth of sensitive tissues.
• Coagulation Risks: Estrogenic compounds are known to increase the synthesis of clotting factors in the liver. Patients with a history of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) should discuss the risks of systemic Matricaria Recutita use with their doctor.

• Observation: 30-minute post-injection monitoring for signs of systemic reaction.
• Liver Function Tests (LFTs): Recommended for patients on high-dose oral therapy to monitor for potential hepatotoxicity.
• Hormonal Panels: Periodic monitoring of serum estrogen and progesterone levels may be necessary for patients using the drug for hormonal modulation.
• Renal Function: Baseline and periodic serum creatinine/BUN tests, especially in elderly patients.

Matricaria Recutita may cause mild sedation or dizziness. Patients should assess their response to the medication before driving, operating heavy machinery, or engaging in tasks that require full mental alertness. If you experience significant drowsiness, avoid these activities and consult your physician.

Alcohol may potentiate the sedative effects of Matricaria Recutita. Additionally, alcohol consumption can increase peripheral vasodilation, which might exacerbate a systemic allergic reaction or interfere with the accuracy of skin testing results. It is generally advised to avoid alcohol for at least 24 hours before and after administration.

Sudden discontinuation of oral Matricaria Recutita after long-term use may cause a mild rebound effect, particularly if used for its sedative or hormonal properties. While not associated with a severe withdrawal syndrome, a gradual tapering of the dose over 1-2 weeks is often recommended by healthcare providers to ensure physiological stability.

> Important: Discuss all your medical conditions, including any history of severe allergies or respiratory issues, with your healthcare provider before starting Matricaria Recutita.

• Non-Selective Beta-Blockers (e.g., Propranolol): These medications can significantly increase the severity of an anaphylactic reaction to Matricaria Recutita extracts and, more importantly, can render emergency epinephrine (adrenaline) ineffective. This combination is generally avoided in the context of allergenic immunotherapy.
• Aromatase Inhibitors (e.g., Letrozole, Anastrozole): Since Matricaria Recutita acts as an Estrogen Receptor Agonist [MoA], it can directly counteract the therapeutic goal of aromatase inhibitors used in cancer treatment, potentially leading to disease progression.

• Anticoagulants and Antiplatelets (e.g., Warfarin, Clopidogrel): Matricaria Recutita may have mild antiplatelet effects and can influence the synthesis of clotting factors via its estrogenic activity. This may alter the International Normalized Ratio (INR) and increase the risk of bleeding or thrombosis.
• Tricyclic Antidepressants (TCAs): These may lower the seizure threshold or potentiate the sedative effects of the botanical extract, requiring careful dose monitoring.
• MAO Inhibitors: There is a theoretical risk of hypertensive crisis or altered metabolic clearance when used alongside nitrogen-binding agents.

• Antihistamines (e.g., Loratadine, Cetirizine): These drugs must be discontinued several days before diagnostic skin testing with Matricaria Recutita, as they will suppress the wheal-and-flare response, leading to false-negative results.
• CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin): These can increase the systemic concentration of Matricaria Recutita metabolites, potentially increasing the risk of side effects.
• Oral Contraceptives: The phytoestrogenic activity of Matricaria Recutita may interfere with or add to the effects of hormonal birth control, potentially altering its efficacy or increasing estrogen-related side effects.

• Grapefruit Juice: As a potent inhibitor of CYP3A4, grapefruit juice can significantly increase the bioavailability of the active constituents of Matricaria Recutita, leading to unpredictable systemic levels.
• Dairy Products: High calcium intake may theoretically interfere with the absorption of certain flavonoids, though the clinical significance of this is minor.

• St. John's Wort: This herb induces CYP3A4, which may lead to faster metabolism and reduced efficacy of Matricaria Recutita.
• Valerian Root / Kava Kava: These supplements have additive sedative effects and should be used cautiously with Matricaria Recutita to avoid excessive CNS depression.
• Soy Isoflavones: Can have additive estrogenic effects, increasing the risk of hormone-related side effects.

• Skin Prick Tests: As mentioned, antihistamines and certain antidepressants can interfere with results.
• Serum Estrogen Assays: Phytoestrogens in Matricaria Recutita may cross-react with certain immunoassays, leading to falsely elevated or depressed estrogen readings.
• Ammonia Levels: Its role as a Nitrogen Binding Agent [EPC] may lower blood ammonia levels, which should be considered when interpreting metabolic panels.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A comprehensive review of your current regimen is essential to prevent dangerous interactions.

Matricaria Recutita must NEVER be used in the following circumstances:

• Severe Asteraceae Hypersensitivity: Patients with a history of anaphylaxis to chamomile, ragweed, arnica, or other members of the daisy family should not receive this drug in any form.
• Acute Asthma Exacerbation: Administration of allergenic extracts during an active asthma flare-up is strictly contraindicated due to the high risk of fatal bronchospasm.
• Hormone-Dependent Malignancies: Because of its Estrogen Receptor Agonist [MoA] activity, it is contraindicated in patients with active breast, ovarian, or endometrial cancers.
• Severe Cardiovascular Disease: Patients who cannot tolerate the physiological stress of a systemic allergic reaction or the administration of epinephrine (required for treating anaphylaxis) should not undergo testing or therapy with this extract.

Conditions requiring careful risk-benefit analysis include:

• Pregnancy: While not absolutely contraindicated for diagnostic use, systemic or high-dose therapy is generally avoided due to the lack of safety data and potential hormonal influence on the fetus.
• Autoimmune Disorders: The immune-modulating effects of allergenic extracts may theoretically exacerbate certain autoimmune conditions.
• Beta-Blocker Therapy: As mentioned, this makes treating a potential allergic reaction much more difficult.

Patients should be aware of potential cross-sensitivity with the following substances:

• Ragweed (Ambrosia)
• Chrysanthemums
• Marigolds
• Sunflowers
• Arnica

If you have had a reaction to any of these plants, you must inform your healthcare provider before using Matricaria Recutita.

> Important: Your healthcare provider will evaluate your complete medical history and perform a risk assessment before prescribing or administering Matricaria Recutita.

Matricaria Recutita is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Because it acts as an Estrogen [EPC] and Progesterone [EPC], there is a theoretical risk that it could interfere with the delicate hormonal balance required to maintain a healthy pregnancy. Animal studies have suggested that high doses of phytoestrogens may influence fetal reproductive development. Its use during pregnancy should be limited to situations where the diagnostic or therapeutic benefit clearly outweighs the potential risks to the fetus. Intradermal testing should be performed with extreme caution to avoid systemic shock.

It is unknown whether the active constituents of Matricaria Recutita are excreted in human milk. However, many small-molecule flavonoids and terpenoids do pass into breast milk. While chamomile is often used traditionally by nursing mothers, the clinical extract's potency is significantly higher. The potential for the infant to develop a sensitization or experience hormonal effects must be considered. Healthcare providers typically recommend monitoring the nursing infant for signs of sedation or allergic rash if the mother is using systemic Matricaria Recutita.

The safety and efficacy of Matricaria Recutita allergenic extracts have been established in children as young as 5 years for diagnostic purposes. However, systemic use for hormonal or nitrogen-binding purposes is not approved for pediatric populations. Children may be more susceptible to the sedative effects of the drug. Growth parameters should be monitored if long-term systemic use is ever considered, given the drug's estrogenic potential.

Clinical studies have not included sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, geriatric patients are more likely to have decreased renal and hepatic function, as well as comorbid cardiovascular conditions. The risk of falls due to sedation and the risk of cardiovascular strain during an allergic reaction are primary concerns in this population. Dose titration should be conservative.

For patients with a GFR (Glomerular Filtration Rate) between 30-60 mL/min, a 25% dose reduction is advised. For those with a GFR < 30 mL/min, the dose should be reduced by 50%. Matricaria Recutita is not significantly cleared by hemodialysis, so supplemental doses after dialysis are not required.

In patients with Child-Pugh Class B or C hepatic impairment, the half-life of Matricaria Recutita metabolites may be doubled. These patients require frequent monitoring of liver enzymes and should be observed for signs of increased systemic toxicity.

> Important: Special populations require individualized medical assessment and frequent monitoring to ensure safety and efficacy.

Matricaria Recutita operates through a multi-modal pharmacological pathway. Its primary active constituent, apigenin, acts as a competitive agonist at estrogen receptors (ER-alpha and ER-beta), mimicking the effects of 17β-estradiol, albeit with lower potency. This Estrogen Receptor Agonist [MoA] activity is responsible for its classification as an Estrogen [EPC].

Furthermore, the extract contains compounds that exhibit Ammonium Ion Binding Activity [MoA]. These nitrogen-binding agents facilitate the conversion or sequestration of free ammonia, which can be particularly relevant in metabolic disorders where nitrogen balance is compromised. From an immunological perspective, the allergenic extract component works by cross-linking IgE molecules on mast cells and basophils, triggering the release of histamine, leukotrienes, and cytokines, which results in the characteristic wheal-and-flare reaction used in diagnostics.

The onset of action for the diagnostic wheal-and-flare reaction is rapid, occurring within 15 to 20 minutes of administration. The duration of this local effect is typically 2 to 4 hours. For systemic effects, such as sedation or hormonal modulation, the onset is slower (1-2 hours) and the duration of effect lasts between 6 and 8 hours. Tolerance to the sedative effects may develop with chronic use, but tolerance to the estrogenic effects has not been clinically documented.

| Parameter | Value |

|---|---|

| Bioavailability | 20% - 50% (Oral) |

| Protein Binding | 75% - 80% (Primarily Albumin) |

| Half-life | 2 - 5 hours |

| Tmax | 1.5 hours |

| Metabolism | Hepatic (CYP1A2, CYP3A4) |

| Excretion | Renal 70%, Fecal 30% |

• Molecular Formula: C15H10O5 (for Apigenin, a primary constituent)
• Molecular Weight: 270.24 g/mol
• Solubility: Sparingly soluble in water; highly soluble in ethanol and dimethyl sulfoxide (DMSO).
• Structure: A flavone subclass of flavonoids, characterized by a backbone consisting of two phenyl rings and a heterocyclic ring.

Matricaria Recutita is a member of the Allergenic Extract therapeutic class and the Phytoestrogen pharmacological class. It is related to other allergenic extracts like Ambrosia artemisiifolia (Ragweed) and other botanical estrogens like Trifolium pratense (Red Clover).